Ein Überblick über die Osteoimmunologie

ZUSAMMENFASSUNG

Osteoimmunologie beschreibt die Wechselwirkungen zwischen dem Immunsystem und dem Knochenstoffwechsel. Besonders bei rheumatischen Erkrankungen sind die Auswirkungen der Osteoimmunologie gut ersichtlich, da viele entzündliche rheumatische Erkrankungen mit lokalen Knochenerosionen und Osteoporose einhergehen. Die Zellen des Immunsystems, welche die chronische Entzündung aufrechterhalten, führen gleichzeitig zu einer Stimulation der Osteoklastogenese und somit der Knochenresorption. Osteoblasten hingegen werden in ihrer Funktion unterdrückt und damit bleiben die knochenregenerativen Prozesse aus. Die Aufschlüsselung der zugrundeliegenden Mechanismen der Knochendestruktion ist aktuell Gegenstand intensiver Forschung und könnte zu neuen therapeutischen Strategien führen, um die Knochengesundheit bei Patienten mit rheumatischen Erkrankungen aufrechtzuerhalten. Dieser Artikel gibt einen kurzen Überblick über das Feld der Osteoimmunologie und fokussiert insbesondere auf den Einfluss des Immunsystems auf die Knochenresorption.

SUMMARY

Osteoimmunology describes the interaction between the bone and immune systems. Rheumatic diseases in particular are prototypical osteoimmunological diseases as the chronic inflammatory processes lead to profound local and systemic bone destruction. Cells of the immune system, which drive chronic inflammation, also stimulate osteoclastogenesis and bone resorption and concomitantly inhibit osteoblast function and bone regeneration, thus leading to bone loss. Understanding the underlying mechanisms of osteoimmunology is of great scientific and medical interest and will aid in identifying new targets to maintain bone health in affected patients. This review gives an overview of the field of osteoimmunology with a focus on mechanisms leading to enhanced bone resorption.

Schlüsselwörter

Osteoimmunologie - rheumatoide Arthritis - Parodontitis - Knochenverlust - Zytokine - Osteoklasten

Keywords

Osteoimmunology - rheumatoid arthritis - parodontitis - bone loss - cytokines - osteoclasts

Publication History

Article published online:
26 February 2021

• Literaturverzeichnis

• 1 Horton JE, Raisz LG, Simmons HA. et al Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science (80-) 1972; 177: 793-795 DOI: 10.1126/science.177.4051.793.
• 2 Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408: 535-536 DOI: 10.1038/35046196.
• 3 Takayanagi H, Ogasawara K, Hida S. et al T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000; 408: 600-605 DOI: 10.1038/35046102.
• 4 Agrawal M, Arora S, Li J. et al Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 2011; 9: 251-257 DOI: 10.1007/s11914-011-0077-9.
• 5 Attia EAS, Khafagy A, Abdel-Raheem S. et al Assessment of osteoporosis in psoriasis with and without arthritis: Correlation with disease severity. Int J Dermatol 2011; 50: 30-35 DOI: 10.1111/j.1365-4632.2010.04600.x.
• 6 Haugeberg G, Uhlig T, Falch JA. et al Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum 2000; 43: 522-530 DOI: 10.1002/1529-0131(200003)43:3 < 522::AID-ANR7 > 3.0.CO;2-Y.
• 7 Gruber R. Osteoimmunology: Inflammatory osteolysis and regeneration of the alveolar bone. J Clin Periodontol 2019; 46: 52-69 DOI: 10.1111/jcpe.13056.
• 8 Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation and ageing. Immun Ageing 2005: 2 DOI: 10.1186/1742-4933-2-14
• 9 Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol 2019; 19: 626-642 DOI: 10.1038/s41577-019-0178-8.
• 10 Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep 2014; 3: 481 DOI: 10.1038/bonekey.2013.215.
• 11 Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253 DOI: 10.1007/s001090100226.
• 12 Dallas SL, Prideaux M, Bonewald LF. The osteocyte: An endocrine cell . . . and more. Endocr Rev 2013; 34: 658-690 DOI: 10.1210/er.2012-1026.
• 13 Ono T, Hayashi M, Sasaki F. et al RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen 2020: 40 DOI: 10.1186/s41232-019-0111-3
• 14 Anderson DM, Maraskovsky E, Billingsley WL. et al A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179 DOI: 10.1038/36593.
• 15 Mueller CG, Hess E. Emerging functions of RANKL in lymphoid tissues. Front Immunol. 2012: 3 DOI: 10.3389/fimmu.2012.00261
• 16 Duheron V, Hess E, Duval M. et al Receptor activator of NF-κB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci U S A 2011; 108: 5342-5347 DOI: 10.1073/pnas.1013054108.
• 17 Hofbauer LC, Khosla S, Dunstan CR. et al The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12 DOI: 10.1359/jbmr.2000.15.1.2.
• 18 Singh K, Piprode V, Mhaske ST. et al IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice. J Immunol 2018; 200: 595-606 DOI: 10.4049/jimmunol.1601528.
• 19 Tunyogi-Csapo M, Kis-Toth K, Radacs M. et al Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: Fibroblast-mediated pathologic bone resorption. Arthritis Rheum 2008; 58: 2397-2408 DOI: 10.1002/art.23653.
• 20 Palmqvist P, Lundberg P, Persson E. et al Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 2006; 281: 2414-2429 DOI: 10.1074/jbc.M510160200.
• 21 Mori T, Miyamoto T, Yoshida H. et al IL-1 and TNF -initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011; 23: 701-712 DOI: 10.1093/intimm/dxr077.
• 22 Hartgring SAY, Willis CR, Alcorn D. et al Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum 2010; 62: 2716-2725 DOI: 10.1002/art.27578.
• 23 Lee KA, Kim KW, Kim BM. et al Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis. Arthritis Res Ther 2019: 21 DOI: 10.1186/s13075-019-2070-0
• 24 Marahleh A, Kitaura H, Ohori F. et al TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation. Front Immunol 2019: 10 DOI: 10.3389/fimmu.2019.02925
• 25 Feng W, Guo J, Li M. RANKL-independent modulation of osteoclastogenesis. J Oral Biosci 2019; 61: 16-21 DOI: 10.1016/j.job.2019.01.001.
• 26 Raphael I, Nalawade S, Eagar TN. et al T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 2015; 74: 5-17 DOI: 10.1016/j.cyto.2014.09.011.
• 27 Panitch HS, Hirsch RL, Schindler J. et al Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-1102 DOI: 10.1212/wnl.37.7.1097.
• 28 Schwarting A, Wada T, Kinoshita K. et al IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol 1998; 161: 494-503 Im Internet http://www.jimmunol.org/content/161/1/494
• 29 Cruz A, Khader SA, Torrado E. et al Cutting Edge: IFN-γ Regulates the Induction and Expansion of IL-17-Producing CD4 T Cells during Mycobacterial Infection. J Immunol 2006; 177: 1416-1420 DOI: 10.4049/jimmunol.177.3.1416.
• 30 Nelson BH. IL-2, Regulatory T Cells, and Tolerance. J Immunol 2004; 172: 3983-3988 DOI: 10.4049/jimmunol.172.7.3983.
• 31 Adamopoulos IE, Chao C chi, Geissler R. et al Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther 2010; 12: R29 DOI: 10.1186/ar2936.
• 32 Sato K, Suematsu A, Okamoto K. et al Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-2682 DOI: 10.1084/jem.20061775.
• 33 Yago T, Nanke Y, Kawamoto M. et al IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007; 9: 1-12 DOI: 10.1186/ar2297.
• 34 Glowacki AJ, Yoshizawa S, Jhunjhunwala S. et al Prevention of inflammation-mediated bone loss in murine and canine periodontal disease via recruitment of regulatory lymphocytes. Proc Natl Acad Sci U S A 2013; 110: 18525-18530 DOI: 10.1073/pnas.1302829110.
• 35 Jiao S, Subudhi SK, Aparicio A. et al Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell 2019; 179: 1177-1190.e13 DOI: 10.1016/j.cell.2019.10.029.
• 36 Ueta M, Takaoka K, Yamamura M. et al Effects of TGF-β1 on the migration and morphology of RAW264.7 cells in vitro. Mol Med Rep 2019; 20: 4331-4339 DOI: 10.3892/mmr.2019.10662.
• 37 Krast M, Gorny G, Sells Galvin RJ. et al Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-β regulation of osteoclast differentiation. J Cell Physiol 2004; 200: 99-106 DOI: 10.1002/jcp.20036.
• 38 Chen G, Deng C, Li YP. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8: 272-288 DOI: 10.7150/ijbs.2929.
• 39 Liu D, Yao S, Wise GE. Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. Eur J Oral Sci 2006; 114: 42-49 DOI: 10.1111/j.1600-0722.2006.00283.x.
• 40 Houri-Hoddod Y, Soskolne WA, Halabi A. et al IL-10 gene transfer attenuates P. gingivalis-induced inflammation. J Dent Res 2007; 86: 560-564 DOI: 10.1177/154405910708600614.
• 41 Xiong Y, Yan C, Chen L. et al IL-10 induces MC3T3-E1 cells differentiation towards osteoblastic fate in murine model. J Cell Mol Med 2020; 24: 1076-1086 DOI: 10.1111/jcmm.14832.
• 42 Komatsu N, Okamoto K, Sawa S. et al Pathogenic conversion of Foxp3 + T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62-68 DOI: 10.1038/nm.3432.
• 43 Tsukasaki M, Komatsu N, Nagashima K. et al Host defense against oral microbiota by bone-damaging T cells. Nat Commun 2018; 9: 1-11 DOI: 10.1038/s41467-018-03147-6.
• 44 Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6: 107-116 DOI: 10.1038/nri1780.
• 45 Wang Y, Xiao M, Tao C. et al Inactivation of mTORC1 Signaling in Osterix-Expressing Cells Impairs B-cell Differentiation. J Bone Miner Res 2018; 33: 732-742 DOI: 10.1002/jbmr.3352.
• 46 Onal M, Xiong J, Chen X. et al Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 2012; 287: 29851-29860 DOI: 10.1074/jbc.M112.377945.
• 47 Meednu N, Zhang H, Owen T. et al Production of RANKL by Memory B Cells: A Link between B Cells and Bone Erosion in Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68: 805-816 DOI: 10.1002/art.39489.
• 48 Edwards JCW, Szczepański L, Szechiński J. et al Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N Engl J Med 2004; 350: 2572-2581 DOI: 10.1056/nejmoa032534.
• 49 Oliver-Bell J, Butcher JP, Malcolm J. et al Periodontitis in the absence of B cells and specific anti-bacterial antibody. Mol Oral Microbiol 2015; 30: 160-169 DOI: 10.1111/omi.12082.
• 50 Li Y, Toraldo G, Li A. et al B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109: 3839-3848 DOI: 10.1182/blood-2006-07-037994.
• 51 Hu F, Liu H, Liu X. et al Pathogenic conversion of regulatory B10 cells into osteoclast-priming cells in rheumatoid arthritis. J Autoimmun 2017; 76: 53-62 DOI: 10.1016/j.jaut.2016.09.002.
• 52 Yu P, Hu Y, Liu Z. et al Local induction of B cell interleukin-10 competency alleviates inflammation and bone loss in ligatureinduced experimental periodontitis in mice. Infect Immun 2017: 85 DOI: 10.1128/IAI.00645-16
• 53 Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969 DOI: 10.1038/nri2448.
• 54 Brancato SK, Albina JE. Wound macrophages as key regulators of repair: Origin, phenotype, and function. Am J Pathol 2011; 178: 19-25 DOI: 10.1016/j.ajpath.2010.08.003.
• 55 Guihard P, Danger Y, Brounais B. et al Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 2012; 30: 762-772 DOI: 10.1002/stem.1040.
• 56 Alexander KA, Chang MK, Maylin ER. et al Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res 2011; 26: 1517-1532 DOI: 10.1002/jbmr.354.
• 57 Schlundt C, El Khassawna T, Serra A. et al Macrophages in bone fracture healing: Their essential role in endochondral ossification. Bone 2018; 106: 78-89 DOI: 10.1016/j.bone.2015.10.019.
• 58 Granucci F, Vizzardelli C, Pavelka N. et al Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2001; 2: 882-888 DOI: 10.1038/ni0901-882.
• 59 Arizon M, Nudel I, Segev H. et al Langerhans cells down-regulate inflammation-driven alveolar bone loss. Proc Natl Acad Sci U S A 2012; 109: 7043-7048 DOI: 10.1073/pnas.1116770109.
• 60 Byrne A, Reen DJ. Lipopolysaccharide Induces Rapid Production of IL-10 by Monocytes in the Presence of Apoptotic Neutrophils. J Immunol 2002; 168: 1968-1977 DOI: 10.4049/jimmunol.168.4.1968.
• 61 Moutsopoulos NM, Konkel J, Sarmadi M. et al Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med 2014: 6 DOI: 10.1126/scitranslmed.3007696
• 62 Hashimoto J, Yoshikawa H, Takaoka K. et al Inhibitory effects of tumor necrosis factor alpha on fracture healing in rats. Bone 1989; 10: 453-457 DOI: 10.1016/8756-3282(89)90078-1.
• 63 Lam RS, O’Brien-Simpson NM, Lenzo JC. et al Macrophage Depletion Abates Porphyromonas gingivalis –Induced Alveolar Bone Resorption in Mice . J Immunol 2014; 193: 2349-2362 DOI: 10.4049/jimmunol.1400853.
• 64 Yu VWC, Saez B, Cook C. et al Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J Exp Med 2015; 212: 759-774 DOI: 10.1084/jem.20141843.
• 65 Greenbaum A, Hsu YMS, Day RB. et al CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013; 495: 227-230 DOI: 10.1038/nature11926.
• 66 Raaijmakers MHGP, Mukherjee S, Guo S. et al Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-857 DOI: 10.1038/nature08851.
• 67 Kode A, Manavalan JS, Mosialou I. et al Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 2014; 506: 240-244 DOI: 10.1038/nature12883.
• 68 Fulzele K, Krause DS, Panaroni C. et al Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling. Blood 2013; 121: 930-939 DOI: 10.1182/blood-2012-06-437160.
• 69 Sato M, Asada N, Kawano Y. et al Osteocytes regulate primary lymphoid organs and fat metabolism. Cell Metab 2013; 18: 749-758 DOI: 10.1016/j.cmet.2013.09.014.
• 70 Sreehari S, Naik DR, Eapen M. Osteopetrosis: A rare cause of anemia. Hematol Rev 2011; 3: 1-2 DOI: 10.4081/hr.2011.e1.
• 71 Reeves JD, August CS, Humbert JR. et al Host Defense in Infantile Osteopetrosis. Pediatrics 1979: 64
• 72 Kollet O, Dar A, Shivtiel S. et al Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12: 657-664 DOI: 10.1038/nm1417.
• 73 Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA – J Am Med Assoc 2018; 320: 1360-1372 DOI: 10.1001/jama.2018.13103.